Erika Escartin is a biotechnology executive with 20 years of experience dedicating her career to bringing therapies for rare diseases around the globe. Her most recent role as Head of Global Marketing includes bringing the 3rd product approved in the US and Canada for ALS or amyotrophic lateral sclerosis, a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.  She is a graduate of Trinity College, Hartford CT with a BA in Psychology and Italian Studies and received her MBA from Hult International Business school in Boston, MA. 

She has a rich understanding of Global and US product launches, and extensive experience in marketing, communications, and patient engagement including Strategic Planning, Branding & Positioning, Patient Engagement & Advocacy, Corporate Communications & Investor Relations. 

Erika is a high-energy, leader with demonstrated abilities in strategic and tactical planning, she is fluent in Spanish and lived in Italy for a few years. Erika loves to travel and immerse herself in other cultures. In early 2023 she traveled to the Mara with Basecamp Foundation and immediately fell in love with the richness of the Mara and the beauty of the Maasai. She is very much looking forward to returning in February 2024.

To learn more about Erika please find her LinkedIn profile here: https://www.linkedin.com/in/erika-escartin-32b7a01/